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Antimicrobial resistant (AMR) organisms are increasing globally, threatening to render existing 
treatments ineffective against many infectious diseases.1,2 AMR strains of bacteria, fungi, 
parasites, and viruses prolong illness, increase case fatality, facilitate transmission, and increase 
treatment costs.3,4 In Africa where many health systems are weak, the likelihood of AMR 
increasing and the consequences of AMR infections are particularly high, and drug resistance 
has already been documented for HIV and the pathogens that cause malaria, tuberculosis, 
typhoid, cholera, meningitis, gonorrhoea, and dysentery.5 Patients in these countries have limited 
access to accurate diagnosis and adequate antimicrobial treatment, which can lead to sepsis and 
other life-threatening complications.6,7
Many factors contribute to the emergence, persistence, and transmission of AMR. Although 
AMR strains arise naturally due to genetic changes in replicating microorganisms, their 
emergence is accelerated by inappropriate use of antimicrobial agents in humans, animals, and 
the environment.8 AMR emergence may be amplified by substandard or counterfeit antimicrobials, 
which impair treatment of existing infections and may select for AMR strains.9 Transmission of 
AMR is accelerated by inadequate infection prevention and control in health care facilities, by 
contamination of the food supply with AMR bacteria, by impaired access to potable water, and 
by limitations in public health prevention programmes, including immunisation, sanitation, and 
sexual health.10 Globally, drug resistance causes an estimated 700 000 deaths each year, and if 
current trends continue, AMR could result in over 10 million deaths per year and over $100 
trillion (United States dollars) in lost output globally by 2050.11
Recognising the urgent need for action, the World Health Assembly adopted the Global Action 
Plan on Antimicrobial Resistance in May 2015, and the World Health Organization established the 
Global Antimicrobial Resistance Surveillance System.12 In 2016, African countries committed to 
address AMR as part of the United Nations General Assembly special meeting and, in June 2017, 
committed to accelerate implementation of the International Health Regulations and promote 
Africa’s health security, of which AMR surveillance and control is a core component.13,14 To 
implement these commitments, the Africa Centres for Disease Control and Prevention (Africa 
CDC) officially launched its ‘Framework for Antimicrobial Resistance Control, 2018–2023’ in 
October 2017.15 Established in January 2017, Africa CDC is a ‘specialised technical institution’ of 
the African Union (AU) responsible for strengthening capacity for surveillance and disease 
intelligence, emergency preparedness and response, laboratory systems, information systems, 
and public health research and workforce development in Africa.16
Africa CDC developed its framework with four principles in mind. Firstly, the strategy should 
help advance the Global Action Plan. Secondly, while more information is needed about incidence, 
prevalence, and interventions, Africa CDC should follow the ‘precautionary principle’ and take 
action against resistance now. Thirdly, policy and practice are as important as diagnostic or 
treatment technologies in mitigating AMR. Finally, Africa CDC has an opportunity to leverage 
its unique position in the AU to raise awareness, secure commitments, and influence policy 
at the head of state level. After consultation with subject matter experts in Africa and globally, 
Africa CDC developed a framework that has four objectives: (1) improve surveillance of AMR 
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organisms among humans and animals, (2) delay emergence 
of AMR, (3) limit transmission of AMR and (4) mitigate harm 
among patients infected with AMR organisms. Table 1 lists 
the high priority activities Africa CDC will pursue for each of 
these areas.
Improve surveillance
Understanding the full extent of AMR and its impact in Africa 
is challenged by a lack of continent-wide AMR surveillance 
data, especially for pathogens that require complex testing 
methods.3 Although gains have been made in collecting data 
on resistance to some pathogens, such as HIV, Mycobacterium 
tuberculosis, and Plasmodium spp., several challenges remain, 
including inadequate demand by clinicians for diagnostic 
testing, laboratory infrastructure, resources to continuously 
collect, transport, and test specimens for AMR surveillance, 
use of standardised protocols, quality assurance, systematic 
surveillance of AMR in animals and their products in Africa, 
and collaboration between the human and animal health 
sectors.17,18 Africa CDC’s framework identified several areas 
in which it can strengthen laboratory capacity for surveillance 
in humans and animals.
Delay emergence
Reducing the need for and inappropriate use of antimicrobials 
can help delay emergence of AMR. In human health, 
extensive studies have been conducted in the United States, 
Europe, and other high-income settings on approaches to 
promote prudent antimicrobial prescribing – an approach 
known as antimicrobial stewardship.19 Success has been 
achieved when stewardship programmes include structural 
changes and behavioral modification techniques.20,21,22 
Economic incentives for prescribing vary by country but 
can be particularly problematic when physicians or health 
care facilities rely on antimicrobial sales to fund operations. 
In many settings, persons obtain antimicrobials directly 
from pharmacies with no evaluation by or prescription from 
a physician.23 Additionally, substandard and counterfeit 
antimicrobials are widely available in Africa; substandard 
antimicrobials can promote AMR by containing levels of an 
agent sufficient to exert selective pressure for resistant 
organisms but insufficient levels to kill those organisms.9 
There are limited studies about the effectiveness or essential 
components of antimicrobial stewardship programmes in 
Africa and other resource-limited settings, particularly 
involving the engagement of non-physician prescribers.24
In animals, antimicrobials are used for prophylaxis, treatment, 
and growth promotion, and it is reasonably assumed that most 
antimicrobial consumption occurs during food production, 
not through prescriptions to treat illness. Prudent use in these 
settings is a critical risk management approach to delaying 
emergence, but is challenging, because food producers have a 
strong economic incentive to use antimicrobials and weak 
incentive to use them prudently.25,26 The AU has made a high-
level commitment to food safety, engaging partners from 
multiple sectors, including the industry. Africa CDC can 
leverage this commitment by making policymakers more 
aware of the link between food production, AMR emergence, 
and food-borne illness and by promoting prudent antimicrobial 
use in collaboration with animal health, agriculture, and other 
related authorities.
Limit transmission
Transmission of AMR occurs frequently in health care 
facilities.27 Such transmission can have severe consequences, 
because pathogens in health care facilities are more likely 
to be multi-drug resistant. Hospitalised people are more 
susceptible to these severe illness, and these pathogens can 
also be spread outside of the hospital. The basic components 
of all programmes include: strong political commitment and 
dedicated resources for infection control, strict adherence to 
protocols for hand hygiene and for identification, isolation, 
and management of potentially infectious patients, adequate 
supplies and equipment for patient care, systems for infectious 
waste management, building design, and maintenance to 
reduce transmission, and continuous monitoring of process, 
outcome, and impact indicators.28 The West Africa Ebola 
response demonstrated that effective hospital-based infection 
prevention and control programmes require intensive 
support to initiate and sustain. Africa CDC’s framework, 
therefore focuses primarily on advocacy, policy, and guidance 
to mobilise sufficient resources for infection prevention and 
control.
In animal health, implementation of risk-based food safety 
systems – such as hazard analysis of critical control points, 
TABLE 1: Priority areas for Africa Centres for Disease Control and Prevention 
framework for antimicrobial resistance control, 2018–2023.
Strategic plan area Activity
Improve  
surveillance
Increase the number of tests performed on humans and 
animals for AMR organisms
Increase the proportion of clinical diagnostic laboratories with 
quality assurance programmes
Increase the proportion of public health laboratories with 
quality assurance programmes and international accreditation
Increase the number of national public health laboratories 
conducting surveillance for AMR using standardised protocols 
Increase the number of member states that continuously 
collect, analyse, report, and disseminate data about AMR for 
high priority pathogens in their respective countries
Delay  
emergence
Increase the proportion of physicians adhering to prudent 
antibiotic use guidelines
Increase the proportion of veterinarians and food producers 
adhering to prudent antibiotic use guidelines 
Reduce availability and sales of substandard and counterfeit 
antibiotics
Limit transmission Increase the proportion of health care facilities implementing 
infection control and prevention programmes
Increase the availability and sales of animal products raised 
with prudent antibiotic use
Mitigate harm Increase the number of health care facilities with quality 
diagnostic tests for infection and AMR
Reduce the availability and use of substandard diagnostic 
tests and supplies 
Increase the proportion of physicians and health care facilities 
adhering to guidelines for treatment of susceptible and AMR 
infections in humans
Maintain access to essential antibiotics
Cross-cutting Advocate for policies and laws to enable long-term prevention 
and control of AMR
Civil society engagement 
Develop human resources for AMR surveillance and control 
AMR, antimicrobial resistance.
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good handling practices, and good agricultural practices – 
can reduce the flow of AMR pathogens in food to humans, 
especially when combined with proper nutrition to reduce 
the need for antimicrobials.29
Mitigate harm
Strong antimicrobial stewardship programmes promote 
adherence to clinical treatment guidelines, helping delay 
emergence of AMR and improve outcomes among patients 
already infected with AMR organisms. Diagnostic stewardship 
will also be essential to guide such treatment.30 Substandard 
diagnostic tests and laboratory supplies remain common 
problems across Africa and can lead to AMR when tests lead 
to unnecessary antibiotic treatment. Limiting their availability 
will be challenging, given the large number of health care 
delivery sites that may be using such products and the 
insufficient supply of quality diagnostic tests. A major ethical 
dilemma for Africa CDC’s framework will be to balance 
antibiotic access versus excess.31 Although antibiotic usage is 
excessive at a population level, many vulnerable groups lack 
access to effective antimicrobial treatment. Africa CDC’s 
framework focuses on promoting antimicrobial and diagnostic 
stewardship, while seeking ways to maintain access to life-
saving diagnostics and treatments.
Enablers of Africa Centres for 
Disease Control and Prevention’s 
framework
Laws and policies play a critical role in framing, enabling, 
and protecting public health. Africa CDC will leverage its 
stature and authority as a specialised agency of the AU to 
advocate for laws and policies to monitor, prevent, and 
mitigate AMR. Such policy initiatives, however, can only 
succeed with robust involvement of civil society. To date, 
engagement of civil society for AMR has been challenging, 
because the science can be complex to explain, the threat 
often characterised as distant, patients’ stories of illness and 
death often not told because of under-diagnosis and because 
they occur in marginalised groups, interventions not readily 
distilled into high-impact slogans, and public health agencies 
investing too little in civil society engagement.
To effectively control AMR, each country will need 
leadership and staff that have the education and skills to 
implement AMR control programmes in both human and 
animal health sectors. The most pronounced human 
resources gaps are likely in laboratory services – from bench 
microbiologists to managers – and in health care infection 
prevention and control. Africa CDC and partners are 
working together on a public health workforce strategy for 
the continent and mobilising resources to support hiring, 
training, and retaining of staff. By highlighting the urgency 
and severity of the AMR threat, Africa CDC will advocate 
for both donors and government ministries to allocate more 
funding to laboratory services and infection prevention and 
control personnel.
Implementation of Africa Centres 
for Disease Control and Prevention’s 
framework
From 4–5 April 2018, Africa CDC convened AMR focal 
points from African countries and partners to review the 
Africa CDC AMR framework and prioritise activities for 
the next year. One major conclusion of the meeting was 
that Africa CDC should establish a formal structure to 
coordinate AMR activities within the AU, particularly with 
the AU’s animal health agency (the Inter-African Bureau 
for Animal Resources), across member states, and with 
multilateral and non-governmental partners in Africa. 
Participants proposed that this entity’s first task should be 
to transform the Africa CDC AMR framework into an AU-
wide framework and ensure that it more fully addresses 
AMR issues in animal and environmental health. In 
addition to governance and coordination, participants 
proposed that Africa CDC focus activities in the next year 
on developing and harmonising tools to map and assess 
human and animal diagnostic laboratory capacity for AMR, 
developing guidelines for prudent antimicrobial use in 
humans and in animals that reflect what is currently known 
about AMR in Africa, and developing minimum standards 
for infection prevention and control in health care facilities 
to limit AMR transmission.
Conclusion
Africa CDC’s framework for AMR is broad and aspirational, 
reflecting the urgency and complexity of this public health 
problem and the potential for Africa CDC as an institution 
to help galvanise action and provide guidance to member 
states. Progress in implementing this framework will require 
close coordination across and high-level commitment from 
member states and partners in Africa.
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